ARCA Net Receivables vs Deferred Long Term Liab Analysis

ABIO Stock

USD 3.25 0.24 6.88%

ARCA Biopharma financial indicator trend analysis is way more than just evaluating ARCA Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ARCA Biopharma is a good investment. Please check the relationship between ARCA Biopharma Net Receivables and its Deferred Long Term Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.

Net Receivables vs Deferred Long Term Liab

Net Receivables vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ARCA Biopharma Net Receivables account and Deferred Long Term Liab. At this time, the significance of the direction appears to have no relationship.

The correlation between ARCA Biopharma's Net Receivables and Deferred Long Term Liab is 0.04. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of ARCA Biopharma, assuming nothing else is changed. The correlation between historical values of ARCA Biopharma's Net Receivables and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of ARCA Biopharma are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Net Receivables i.e., ARCA Biopharma's Net Receivables and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

0.04

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Net Receivables

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from ARCA Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ARCA Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.At this time, ARCA Biopharma's Selling General Administrative is very stable compared to the past year. As of the 2nd of May 2024, Enterprise Value Over EBITDA is likely to grow to 1.82, while Issuance Of Capital Stock is likely to drop 0.00.

	2021	2022	2023	2024 (projected)
Net Interest Income	13K	675K	1.8M	1.9M
Interest Income	13K	675K	1.8M	1.9M

Net Interest Income Interest Income

ARCA Biopharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Non Currrent Assets Other	Common Stock Total Equity	Current Deferred Revenue	Other Liab
Total Assets		0.21	0.68	0.59	0.99	0.12	-0.97	-0.64	0.51	0.96	0.01	1.0	-0.06	0.72	0.24	0.54	0.78	0.62	0.26	1.0	0.07	0.24	-0.25	-0.24	-0.28	-0.24
Short Long Term Debt Total	0.21		0.02	0.18	0.19	0.99	-0.2	0.19	0.24	0.21	0.38	0.18	-0.51	0.23	0.89	0.4	-0.12	0.38	0.99	0.19	0.96	-0.87	0.67	0.87	0.83	0.87
Other Current Liab	0.68	0.02		0.93	0.69	-0.02	-0.6	-0.37	0.72	0.64	0.04	0.67	-0.09	0.24	0.07	0.84	0.5	0.88	0.01	0.7	-0.13	0.28	-0.26	-0.28	-0.26	-0.28
Total Current Liabilities	0.59	0.18	0.93		0.61	0.15	-0.49	-0.18	0.91	0.54	0.26	0.57	-0.22	0.07	0.23	0.87	0.33	0.98	0.14	0.61	-0.01	0.08	-0.03	-0.08	-0.05	-0.08
Total Stockholder Equity	0.99	0.19	0.69	0.61		0.11	-0.96	-0.6	0.51	0.97	0.01	0.98	-0.06	0.67	0.23	0.54	0.76	0.63	0.23	1.0	0.05	0.24	-0.24	-0.24	-0.28	-0.24
Property Plant And Equipment Net	0.12	0.99	-0.02	0.15	0.11		-0.11	0.29	0.2	0.12	0.43	0.09	-0.52	0.14	0.88	0.36	-0.21	0.34	0.98	0.1	0.97	-0.91	0.74	0.91	0.89	0.91
Net Debt	-0.97	-0.2	-0.6	-0.49	-0.96	-0.11		0.65	-0.39	-0.98	0.2	-0.98	0.01	-0.75	-0.24	-0.5	-0.79	-0.52	-0.25	-0.97	-0.06	-0.25	0.33	0.25	0.3	0.25
Retained Earnings	-0.64	0.19	-0.37	-0.18	-0.6	0.29	0.65		-0.13	-0.59	0.36	-0.66	-0.15	-0.8	0.02	-0.22	-0.97	-0.15	0.11	-0.63	0.27	-0.57	0.71	0.57	0.63	0.57
Accounts Payable	0.51	0.24	0.72	0.91	0.51	0.2	-0.39	-0.13		0.43	0.39	0.48	-0.23	0.02	0.29	0.74	0.25	0.91	0.17	0.51	0.02	0.0	0.07	0.0	0.02	0.0
Cash	0.96	0.21	0.64	0.54	0.97	0.12	-0.98	-0.59	0.43		-0.18	0.97	-0.04	0.69	0.26	0.54	0.75	0.57	0.25	0.98	0.07	0.23	-0.3	-0.23	-0.27	-0.23
Non Current Assets Total	0.01	0.38	0.04	0.26	0.01	0.43	0.2	0.36	0.39	-0.18		-0.05	-0.35	-0.21	0.27	0.06	-0.3	0.31	0.37	-0.04	0.41	-0.49	0.73	0.49	0.51	0.49
Cash And Short Term Investments	1.0	0.18	0.67	0.57	0.98	0.09	-0.98	-0.66	0.48	0.97	-0.05		-0.03	0.74	0.22	0.53	0.8	0.59	0.23	1.0	0.04	0.27	-0.29	-0.27	-0.31	-0.27
Net Receivables	-0.06	-0.51	-0.09	-0.22	-0.06	-0.52	0.01	-0.15	-0.23	-0.04	-0.35	-0.03		0.09	-0.49	-0.13	0.1	-0.3	-0.47	-0.05	-0.52	0.54	-0.5	-0.54	-0.55	-0.54
Common Stock Shares Outstanding	0.72	0.23	0.24	0.07	0.67	0.14	-0.75	-0.8	0.02	0.69	-0.21	0.74	0.09		0.26	0.25	0.82	0.14	0.35	0.7	0.2	0.19	-0.38	-0.19	-0.28	-0.19
Non Current Liabilities Total	0.24	0.89	0.07	0.23	0.23	0.88	-0.24	0.02	0.29	0.26	0.27	0.22	-0.49	0.26		0.42	0.04	0.4	0.87	0.23	0.83	-0.73	0.5	0.73	0.7	0.73
Other Current Assets	0.54	0.4	0.84	0.87	0.54	0.36	-0.5	-0.22	0.74	0.54	0.06	0.53	-0.13	0.25	0.42		0.33	0.91	0.37	0.56	0.22	-0.07	-0.07	0.07	0.08	0.07
Other Stockholder Equity	0.78	-0.12	0.5	0.33	0.76	-0.21	-0.79	-0.97	0.25	0.75	-0.3	0.8	0.1	0.82	0.04	0.33		0.3	-0.04	0.79	-0.22	0.54	-0.65	-0.54	-0.6	-0.54
Total Liab	0.62	0.38	0.88	0.98	0.63	0.34	-0.52	-0.15	0.91	0.57	0.31	0.59	-0.3	0.14	0.4	0.91	0.3		0.33	0.63	0.19	-0.09	0.09	0.09	0.11	0.09
Property Plant And Equipment Gross	0.26	0.99	0.01	0.14	0.23	0.98	-0.25	0.11	0.17	0.25	0.37	0.23	-0.47	0.35	0.87	0.37	-0.04	0.33		0.23	0.97	-0.83	0.63	0.83	0.79	0.83
Total Current Assets	1.0	0.19	0.7	0.61	1.0	0.1	-0.97	-0.63	0.51	0.98	-0.04	1.0	-0.05	0.7	0.23	0.56	0.79	0.63	0.23		0.05	0.26	-0.28	-0.26	-0.3	-0.26
Short Term Debt	0.07	0.96	-0.13	-0.01	0.05	0.97	-0.06	0.27	0.02	0.07	0.41	0.04	-0.52	0.2	0.83	0.22	-0.22	0.19	0.97	0.05		-0.92	0.74	0.92	0.88	0.92
Common Stock	0.24	-0.87	0.28	0.08	0.24	-0.91	-0.25	-0.57	0.0	0.23	-0.49	0.27	0.54	0.19	-0.73	-0.07	0.54	-0.09	-0.83	0.26	-0.92		-0.89	-1.0	-0.99	-1.0
Non Currrent Assets Other	-0.25	0.67	-0.26	-0.03	-0.24	0.74	0.33	0.71	0.07	-0.3	0.73	-0.29	-0.5	-0.38	0.5	-0.07	-0.65	0.09	0.63	-0.28	0.74	-0.89		0.89	0.91	0.89
Common Stock Total Equity	-0.24	0.87	-0.28	-0.08	-0.24	0.91	0.25	0.57	0.0	-0.23	0.49	-0.27	-0.54	-0.19	0.73	0.07	-0.54	0.09	0.83	-0.26	0.92	-1.0	0.89		0.99	1.0
Current Deferred Revenue	-0.28	0.83	-0.26	-0.05	-0.28	0.89	0.3	0.63	0.02	-0.27	0.51	-0.31	-0.55	-0.28	0.7	0.08	-0.6	0.11	0.79	-0.3	0.88	-0.99	0.91	0.99		0.99
Other Liab	-0.24	0.87	-0.28	-0.08	-0.24	0.91	0.25	0.57	0.0	-0.23	0.49	-0.27	-0.54	-0.19	0.73	0.07	-0.54	0.09	0.83	-0.26	0.92	-1.0	0.89	1.0	0.99

Click cells to compare fundamentals

ARCA Biopharma Account Relationship Matchups

ARCA Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	8.5M	50.4M	54.9M	43.1M	37.9M	34.9M
Other Current Liab	508K	1.7M	2.4M	798K	561K	533.0K
Total Current Liabilities	926K	3.5M	3.5M	1.1M	637K	605.2K
Total Stockholder Equity	7.6M	46.5M	51.0M	41.7M	37.0M	22.4M
Property Plant And Equipment Net	32K	449K	485K	368K	257K	244.2K
Net Debt	(8.3M)	(48.7M)	(53.0M)	(42.2M)	(37.2M)	(35.3M)
Retained Earnings	(144.4M)	(154.2M)	(173.5M)	(183.4M)	(188.7M)	(198.2M)
Accounts Payable	418K	1.8M	1.1M	334K	362K	343.9K
Cash	8.4M	49.1M	53.4M	42.4M	37.4M	23.0M
Non Current Assets Total	56K	461K	503K	386K	269.0K	255.5K
Cash And Short Term Investments	8.4M	49.1M	53.4M	42.4M	37.4M	34.6M
Common Stock Shares Outstanding	1.3M	4.7M	13.9M	14.4M	14.4M	15.1M
Liabilities And Stockholders Equity	8.5M	50.4M	54.9M	43.1M	37.9M	34.9M
Non Current Liabilities Total	418K	409K	383K	280K	204.0K	193.8K
Other Current Assets	117K	897K	1.1M	254K	161K	153.0K
Other Stockholder Equity	152.0M	200.7M	224.5M	225.1M	225.7M	200.1M
Total Liab	926K	3.9M	3.9M	1.4M	841K	799.0K
Property Plant And Equipment Gross	32K	449K	680K	572K	469K	445.6K
Total Current Assets	8.5M	50.0M	54.4M	42.7M	37.6M	29.0M
Property Plant Equipment	10K	449K	485K	368K	331.2K	314.6K
Net Tangible Assets	7.6M	46.5M	51.0M	41.7M	47.9M	24.1M
Retained Earnings Total Equity	(131.0M)	(138.9M)	(144.4M)	(154.2M)	(138.7M)	(145.7M)
Capital Surpluse	141.3M	145.0M	152.0M	200.7M	230.8M	136.2M
Net Invested Capital	7.6M	46.5M	51.0M	41.7M	37.0M	31.5M
Net Working Capital	7.6M	46.5M	50.9M	41.6M	37.0M	31.4M

Pair Trading with ARCA Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARCA Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with ARCA Stock

0.71

ELYM

Eliem Therapeutics Trending

Pair Corr

Moving against ARCA Stock

0.91	PRFX	PainreformLtd	Pair Corr
0.9	JNJ	Johnson Johnson Aggressive Push	Pair Corr
0.87	EVOK	Evoke Pharma	Pair Corr
0.85	GILD	Gilead Sciences	Pair Corr
0.8	GNLX	Genelux Common	Pair Corr

The ability to find closely correlated positions to ARCA Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARCA Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARCA Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARCA Biopharma to buy it.

The correlation of ARCA Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARCA Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARCA Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ARCA Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether ARCA Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ARCA Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arca Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arca Biopharma Stock:

How To Invest In ARCA

Details

Is ARCA Stock a good investment?

Details

What is ARCA Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for ARCA Stock analysis

When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.

	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk

Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.42)

Return On Assets

(0.12)

Return On Equity

(0.16)

The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ARCA Net Receivables vs Deferred Long Term Liab Analysis

Net Receivables vs Deferred Long Term Liab

Net Receivables vs Deferred Long Term Liab Correlation Analysis

Correlation Coefficient

Net Receivables

Deferred Long Term Liab

ARCA Biopharma fundamental ratios Correlations

ARCA Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ARCA Biopharma fundamental ratios Accounts

Pair Trading with ARCA Biopharma

Moving together with ARCA Stock

Moving against ARCA Stock

Complementary Tools for ARCA Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Liab	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets

Other Liab	- 1.0	Common Stock
Common Stock Total Equity	- 1.0	Common Stock
Current Deferred Revenue	- 0.99	Common Stock
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Other Stockholder Equity	- 0.97	Retained Earnings